#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Noonan syndrome Hypereosinophilic syndrome Mitochondrial myopathy Anaplastic large cell lymphoma T- and null-cell types Chronic hepatitis B Corneal neovascularisation Type IIa hyperlipidaemia Liver transplant rejection Piriformis syndrome Mucopolysaccharidosis III Gastrointestinal disorder Marginal zone lymphoma Congenital nephrogenic diabetes insipidus Phaeochromocytoma Heritable pulmonary arterial hypertension More trials…

    Learn about Rare Diseases

    Cystic fibrosis – Basic Information Angelman’s syndrome Gaucher’s disease type I – Basic Information CADASIL – Treatment Loeys-Dietz syndrome – Diagnostics Waldenstrom’s macroglobulinaemia recurrent Primary hyperoxaluria – Life with Disease Sjogren’s syndrome – Basic Information Adrenocortical carcinoma – Trials in Disease Angiosarcoma recurrent – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Opium, Standardized Powdered Anhydrous Glucose Bp Namilumab Nmd670 4-Hydroxy-N-Desmethyltamoxifen Gad20-209-Fsp-A1 Olive Oil, Refined Rotigotine Fexofenadine Hydrochloride Holcus Lanatus Pollen Extract Kbp-336 Benzathine Benzylpenicillin Risedronate Sodium Leuprorelin Acetate Progesterone Sym025 ASP2957 NALDEMEDINE Testosterone Metformin Embonate More therapies…

    Learn about Your Condition

    Raynaud's phenomenon Plasma cell leukaemia Eosinophilic gastritis Mitral valve prolapse Porphyria non-acute Influenza Optic glioma Pancreatitis acute Binge eating Supranuclear palsy Nicotine dependence Follicular lymphoma stage II HIV infection Colorectal cancer Body mass index increased More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Cliniques Universitaires Saint-Luc

Cliniques Universitaires Saint-Luc

Hippokrateslaan 10, Batiment 54, Woluwe-Saint-Lambert, 1200, Belgium

Want to learn more about this study or check if you can participate? Contact us.

  • Long-Term Safety Study of Venetoclax for Patients with Chronic Lymphocytic Leukemia, Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Acute Leukemia

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Non-Hodgkin’s lymphoma
    • Waldenstrom’s macroglobulinaemia
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Venetoclax
    Belgium Denmark France Greece Ireland Poland +1

  • Study of Pembrolizumab in Patients with Esophageal Cancer Undergoing Chemoradiotherapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Oesophageal carcinoma
    Investigated Drugs:
    • Folinic Acid
    • Calcium Folinate
    • Cisplatin
    Belgium Czechia Denmark Estonia France Germany +4

  • Study on Long-term Safety of Ustekinumab for Children with Crohn’s Disease, Juvenile Psoriatic Arthritis, or Ulcerative Colitis

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Juvenile psoriatic arthritis
    • Crohn’s disease
    • Colitis ulcerative
    Investigated Drugs:
    • Ustekinumab
    Belgium France Germany Hungary Italy Poland +1

  • Study of Nivolumab and Ipilimumab for Patients with Stage 3 Non-Small Cell Lung Cancer Not Suitable for Surgery

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer stage III
    Investigated Drugs:
    • Ipilimumab
    • Carboplatin
    • Cisplatin
    Belgium France Germany Greece Ireland Italy +5

  • Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Hodgkin’s disease
    Investigated Drugs:
    • Cisplatin
    • Gemcitabine
    • Pegfilgrastim
    Belgium Denmark The Netherlands

  • Study on the Effectiveness and Safety of OG-6219 and Naproxen Sodium for Women Aged 18-49 with Moderate to Severe Endometriosis Pain

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Endometriosis
    Investigated Drugs:
    • For-6219
    • Naproxen Sodium
    Belgium Bulgaria Czechia France Germany Hungary +4

  • Study on Treatment for Recurrent Platinum-Sensitive Ovarian, Peritoneal, or Fallopian Tube Cancer Using Carboplatin and Mirvetuximab Soravtansine in Eligible Patients

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Fallopian tube cancer
    • Ovarian epithelial cancer
    Investigated Drugs:
    • Prednisolone Acetate
    • Carboplatin
    • Mirvetuximab Soravtansine
    Belgium Ireland Spain

  • Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • (3S)-3-[6-[4-[[1-[4-[(1R,2S)-6-Hydroxy-2-Phenyl-1,2,3,4-Tetrahydronaphthalen-1-Yl]Phenyl]Piperidin-4-Yl]Methyl]Piperazin-1-Yl]-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Fulvestrant
    Austria Belgium Bulgaria Czechia Finland France +9

  • Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

    Not recruiting

    3 1
    Investigated Diseases:
    • Hidradenitis
    Investigated Drugs:
    • 4-[3-(Cyanomethyl)-3-(3′,5′-Dimethyl-1H,1’H-[4,4′-Bipyrazol]-1-Yl)Azetidin-1-Yl]-2,5-Difluoro-N-[(2S)-1,1,1-Trifluoropropan-2-Yl]Benzamide
    Austria Belgium Czechia France Germany Greece +3

  • Study on the Effects of Filgotinib for Adults with Active Axial Spondyloarthritis

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Axial spondyloarthritis
    Investigated Drugs:
    • Filgotinib
    Belgium Bulgaria Croatia Czechia Estonia France +9
Previous Page
1 … 60 61 62 63 64 … 67
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!